RK Pharma Inc., a vertically integrated pharmaceutical company specialising in affordable generic pharmaceutical products, is set to receive a $200 million investment from PAG, a global investment firm. With a focus on complex injectables, RK Pharma develops, manufactures, and sells pharmaceutical products through its subsidiaries, Apicore, Archis Pharma, and Aktinos Pharma. The investment will see RK Pharma’s founder and executive chairman, Ravishanker Kovi, and his management team partner with PAG. Kovi, a seasoned biomedical researcher and drug developer, has a track record of successfully bringing drugs to market. This investment marks PAG’s fifth India-focused private equity deal, demonstrating their commitment to the pharmaceutical sector. The funding will enable RK Pharma to accelerate its growth plans, forge new partnerships, and continue developing and launching innovative medicines, further solidifying its position as a leading specialty pharmaceutical company.
Where Industry Meet Trends
Menu
English